National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, V.2.2008.
Singletary, S.E. "Revision of the American Joint Committee on Cancer staging system for breast cancer," Journal of Clinical Oncology, Sep. 1, 2002.
American Cancer Society. Breast Cancer, 2011.
National Cancer Institute: "Breast Cancer Treatment (PDQ)," "Inflammatory Breast Cancer."
PubMed Health: "Breast cancer."
Cancer.Net: "Breast Cancer - Inflammatory: Treatment Options," "What to Know: ASCO's Guideline on Follow-Up Care for Breast Cancer - Recommendations."
American Cancer Society: "Hormone therapy for breast cancer."
Fisher, B. "Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study," Journal of the National Cancer Institute, Nov. 16, 2005.
Howell, A. "Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer," Lancet, Jan 1-7, 2005.
Ginny Mason, RN, BSN, executive director, Inflammatory Breast Cancer Research Foundation.
Guha, M. "PARP inhibitors stumble in breast cancer," Nature Biotechnology, published online May 6, 2011.
American Society of Clinical Oncology. "2006 Update of the Breast Cancer Follow-up and Management Guideline in the Adjuvan Setting," Journal of Clinical Oncology, Nov. 1, 2006.
THIS TOOL DOES NOT PROVIDE MEDICAL ADVICE.
It is intended for informational
purposes only. It is not a substitute for professional medical advice,
diagnosis or treatment. Never ignore professional medical advice in seeking
treatment because of something you have read on the WebMD Site. If you think
you may have a medical emergency, immediately call your doctor or dial